CompletedNot Applicable

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

Germany450 participantsStarted 2021-03-03

Plain-language summary

The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS) * The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study * All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed Exclusion Criteria: * Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC) * Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled * Participation in any other clinical studies Other protocol-defined inclusion/exclusion criteria apply

What they're measuring

Proportion of participants persistence with therapy

Timeframe: Up to 36 months

Trial details

NCT IDNCT05335031

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-06-30

View on ClinicalTrials.gov More Multiple Sclerosis, Relapsing-Remitting trials